Progress in the US With Biosimilars, but Opportunities Remain

Last year was a big year for biosimilars in the United States, with the number of FDA-approved biosimilars nearly doubling and major policy and regulatory developments taking place.

Last year was a big year for biosimilars in the United States, with the number of FDA-approved biosimilars nearly doubling and major policy and regulatory developments taking place in 2018. Kelly Davio, senior editor of AJMC®'s The Center for Biosimilars®, highlights recent progress, how the US market compares with Europe, and what remains to be seen.

You may need to log in to the website to access this podcast.

iTunes

TuneIn

Stitcher

Listen above or through one of these podcast services:

The Center for Biosimilars®

Stakeholders Weigh In on the Key Biosimilar Developments of 2018

Coherus Confirms That It Has Launched Its Pegfilgrastim Biosimilar, Udenyca

FDA Releases Biosimilar Action Plan

Pfizer Launches Epoetin Alfa Biosimilar, Retacrit, at 33.5% Discount to Reference Epogen

Pfizer Becomes Latest to Settle With AbbVie Over Humira

Read more about the stories in this podcast: